Incyte Corporation
0.34 (0.48%)


Draw Mode:

Volume 57,186
Bid Price 70.66
Ask Price 70.69
News -
Day High 70.81


52 Week Range


Day Low 70.51
Company Name Stock Ticker Symbol Market Type
Incyte Corporation INCY NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.34 0.48% 70.65 09:55:55
Open Price Low Price High Price Close Price Prev Close
70.73 70.51 70.81 70.31
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,196 57,186 $ 70.63 $ 4,039,158 - 65.07 - 86.29
Last Trade Time Type Quantity Stock Price Currency
09:56:02 1 $ 70.69 USD

Incyte Corporation Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 15.75B 222.97M 184.07M $ 3.39B $ 340.14M 1.51 46.20
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 185.41k 1.60%

more financials information »

Incyte News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No INCY Message Board. Create One! See More Posts on INCY Message Board See More Message Board Posts

Historical INCY Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week73.5273.85567.8371.071,883,446-2.87-3.9%
1 Month77.0178.0267.8373.671,516,092-6.36-8.26%
3 Months80.1386.2967.8378.631,705,911-9.48-11.83%
6 Months67.4286.2966.13577.481,540,0943.234.79%
1 Year78.9186.2965.0776.471,476,276-8.26-10.47%
3 Years70.20111.0561.9179.961,473,1160.450.64%
5 Years85.06111.0557.0077.461,509,560-14.41-16.94%

Incyte Description

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20230329 14:11:09